DOAC-Remove 50 - removal of Direct Oral Anticoagulats (DOACs) from citrated plasma

Art. No.: 5D-82410B

50 tablets

Product Description

DOAC's (Direct Oral Anticoagulants) can interfere in several blood coagulation assays. DOAC Remove is used for the exclusion of interferences in TT, aPTT, Lupus Anticoagulans, APC Resistance due to Direct Oral Anticoagulant (DOAC) compounds in plasma samples. DOAC removes Dabigatran, Rivaroxaban, Apixaban, Edoxaban or Argatroban from human citrated plasma. DOAC-Remove has no significant effect on acitivities of coagulation factors.

Characteristics

Reliable results in blood coagulation tests which can be trusted
Easy, short handling: Incubation with 0.5 -2.0 mL plasma and centrifugation
Centrifuged plasmas can be used immediately or frozen
Long shelf life
Removes all different DOAC's available: Xarelto-Rivaroxaban; Eliquis-Apixaban ; Lixiana-Edoxaban; Argatra-Argatroban; Pradaxa-Dabigatran

Also available for the removal of DOACs from plasma:

DOAC Remove 250, Art.No. 5D-82410-C, 250 Tests
DP Filter, Art.No. 5D-82412, Columns for removal of DOACs

Available for the in vitro removal of Heparins from plasma:

HEPA-Remove, Art.No. 5D-68179, Heparin Blocker for the in vitro use in the lab only